mem 1003
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2005 (NCT00257673)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- L-type calcium channelANTAGONIST
L-type calcium channel antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mem 1003
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00374920 | Phase 2 | Sep 1, 2006 | Memory Pharmaceuticals, Stanley Medical Research Institute |
| NCT00257673 | Phase 2 | Nov 1, 2005 | Memory Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Memory Pharmaceuticals | For profit | 2 | 2 | 1 | 2005 |
| Stanley Medical Research Institute | Academic/Hospital | 1 | 0 | 1 | 2006 |
2 organizations
Page 1 / 1